<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00358462</url>
  </required_header>
  <id_info>
    <org_study_id>26995-D</org_study_id>
    <secondary_id>05-0143 (protocol number)</secondary_id>
    <secondary_id>U19AI031448</secondary_id>
    <secondary_id>R01AI072728</secondary_id>
    <nct_id>NCT00358462</nct_id>
  </id_info>
  <brief_title>Mycoplasma Genitalium Antibiotic Susceptibility and Treatment (MEGA)</brief_title>
  <official_title>Mycoplasma Genitalium Antibiotic Susceptibility and Treatment: A Randomized Double-blind Trial of the Efficacy of Azithromycin and Doxycycline for Clinical and Microbiological Cure of M. Genitalium in Men With Nongonococcal Urethritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out which of 2 different antibiotics, doxycycline or
      azithromycin, works best against germs that may cause nongonococcal urethritis.

      Study participants will include approximately 1200 men, 16 years of age or older, attending a
      sexually transmitted diseases clinic in Seattle, Washington with clinical signs of urethral
      inflammation (&gt;=5PMNs/HPF on a Gram-stained slide prepared from urethral exudates and/or a
      visible urethral discharge upon examination).

      Urine specimens will be collected and tested for Mycoplasma genitalium and Ureaplasmas. Each
      participant will receive a blinded packet of study medication. Participants will answer an
      enrollment questionnaire and will also receive a log to complete between visits to record
      information about treatment adherence, side effects, symptoms, and sexual activity. All
      subjects will be asked to return for evaluation 3 weeks after the initial clinic visit.
      Subjects who test positive for M. genitalium and/or Ureaplasmas at the initial clinic visit
      will also be asked to return for a third study visit, 6 weeks following the initial clinic
      visit. During follow-up visits, participants will answer a follow-up questionnaire and will
      be re-evaluated for signs of urethritis. Those who were initially positive for M. genitalium
      and/or Ureaplasmas will be re-tested for these organisms.

      Study participants with signs and/or symptoms of urethritis or who test positive for M.
      genitalium or Ureaplasmas at the follow-up study visit will receive another blinded treatment
      packet containing the alternate medication. Those who require additional treatment at the
      6-week visit will be asked to return for a fourth follow-up study visit at 9-10 weeks. Study
      participants who did not test positive for M. genitalium or Ureaplasmas at the initial clinic
      visit, but who continue to demonstrate signs and/or symptoms of infection at their single
      follow-up study visit will treated according to clinic standard of care (after the study
      clinician unblinds their randomly-assigned treatment regimen).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES

      The primary objective of this study is to determine the relative effectiveness of
      azithromycin and doxycycline in eradicating Mycoplasma genitalium and Ureaplasmas among men
      with nongonococcal urethritis (NGU).

      Secondary objectives of this study are to:

        -  determine the sensitivity of persisting organisms to azithromycin and doxycycline by
           performing minimum inhibitory concentration (MIC) testing

        -  determine the relationship between persistence/recurrence of clinical signs and
           persistent/recurrent detection of M. genitalium and Ureaplasmas among men with NGU
           treated with azithromycin or doxycycline, measured by follow-up clinical exams and
           repeated assays performed on specimens collected at follow-up study visits

      STUDY DESCRIPTION

      1200 men with NGU, ages 16 and older, will be enrolled in a randomized double-blinded
      treatment trial. Urine samples, oral swabs, and urethral swabs will be obtained from each
      subject at the initial clinic visit. Urine specimens will be tested for M. genitalium and
      Ureaplasma. Study participants will be randomly assigned to receive one of two pre-packaged
      treatments: active doxycycline plus placebo azithromycin or active azithromycin plus placebo
      doxycycline. Subjects will complete a questionnaire, and will be given a simple standardized
      log in which they will be asked to keep track of adherence to the study drug, record
      solicited adverse events, note when symptoms disappear and/or reappear, and document sexual
      activity between study visits.

      Subjects who test positive for M. genitalium or Ureaplasmas at the initial clinic visit will
      be asked to return for at least two follow-up study visits: at approximately 3 and 6 weeks
      following the initial clinic visit. During follow-up visits, participants will answer a
      follow-up questionnaire and will be re-evaluated for signs of urethritis and re-tested for M.
      genitalium and Ureaplasmas. Study participants with signs and/or symptoms of urethritis or
      who test positive for M. genitalium or Ureaplasmas at the follow-up study visits will receive
      a blinded treatment packet containing the alternate medication, or will be offered open-label
      moxifloxacin if the alternate treatment regimen was administered at the prior follow-up study
      visit. If additional treatment is administered at the 6-week follow-up study visit, a fourth
      study visit will be scheduled to occur approximately 9 or 10 weeks following the initial
      clinic visit.

      Study participants who were negative for M. genitalium and Ureaplasma at enrollment will be
      asked to return for evaluation for a single follow-up study visit, approximately 3 weeks
      after the initial clinic visit. At this visit they will complete the follow-up questionnaire
      and provide specimens for future testing.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mITT Analysis of Eradication of M. Genitalium at First Follow-up Study Visit</measure>
    <time_frame>approximately 3 weeks after initial study visit (allowable window is 2-5 weeks after initial study visit)</time_frame>
    <description>Microbiologic cure of M. genitalium at first follow-up visit (defined as a negative in-house PCR test performed on urine)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>mITT Analysis of Eradication of U. Urealyticum at First Follow-up Visit</measure>
    <time_frame>3 weeks (allowable window 2-5)</time_frame>
    <description>Microbiologic cure, defined as negative PCR for U. urealyticum (if cultured), or negative culture at first follow-up visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Minimum Inhibitory Concentrations (MIC) of All Cultivable Strains of M. Genitalium and Ureaplasmas</measure>
    <time_frame>on-going</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cure as Measured by the Absence of Recurrent or Persistent Signs and/or Symptoms of Urethral Infection Among Case Subjects Who Were Positive for M. Genitalium or Ureaplasmas at the Initial Study Visit</measure>
    <time_frame>approximately 3 weeks after initial study visit (allowable window is 2-5 weeks after initial study visit)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">606</enrollment>
  <condition>Urethritis</condition>
  <arm_group>
    <arm_group_label>Active azithromycin+placebo doxycycline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active azithromycin (1g) and placebo doxycycline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active doxycycline+placebo azithromycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active doxycycline and placebo azithromycin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>two 500mg tablets or four 250mg tablets administered as a single dose</description>
    <arm_group_label>Active azithromycin+placebo doxycycline</arm_group_label>
    <other_name>Zithromax</other_name>
    <other_name>Zmax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>one 100mg capsule administered twice daily for seven days</description>
    <arm_group_label>Active doxycycline+placebo azithromycin</arm_group_label>
    <other_name>Doryx</other_name>
    <other_name>Doxychel</other_name>
    <other_name>Monodox</other_name>
    <other_name>Oracea</other_name>
    <other_name>Periostat</other_name>
    <other_name>Vibra-Tabs</other_name>
    <other_name>Vibramycin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has a visible urethral discharge or greater than or equal to 5 polymorphonuclear
             leukocytes (PMNs) per high power field on a Gram-stained slide of a urethral swab
             sample

          -  Possesses and is willing to disclose valid contact information for follow-up

          -  English-speaking

          -  Gives informed consent

          -  Exhibits understanding of study procedures

          -  Exhibits ability to comply with study procedures for the entire length of the study

        Exclusion Criteria:

          -  Has previously participated in this study

          -  Has taken antibiotics within the prior month

          -  Has known allergies to tetracyclines or azithromycin

          -  Is being treated with any of the following: warfarin, ergot derivatives, pimozide
             (Orap), propafenone (Rytmonorm, Rythmol), disopyramide (Norpace, Rythmodan), rifampin,
             digoxin, isotretinoin, or methotrexate

          -  Has received a kidney, heart, or lung transplant.

          -  Is undertaking concomitant systemic steroid therapy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa E Manhart, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Public Health -- Seattle &amp; King County Sexually Transmitted Diseases Clinic located at Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2006</study_first_submitted>
  <study_first_submitted_qc>July 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2006</study_first_posted>
  <results_first_submitted>February 1, 2013</results_first_submitted>
  <results_first_submitted_qc>February 1, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 8, 2013</results_first_posted>
  <last_update_submitted>February 1, 2013</last_update_submitted>
  <last_update_submitted_qc>February 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Lisa Manhart</investigator_full_name>
    <investigator_title>Study Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>NGU, M genitalium, Ureaplasma, azithromycin, doxycycline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease Susceptibility</mesh_term>
    <mesh_term>Urethritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Men were recruited from a sexually transmitted diseases clinic in Seattle, Washington from January 2007 to July 2011</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Active Azithromycin + Placebo Doxycycline</title>
          <description>Azithromycin : two 500mg tablets or four 250mg tablets administered as a single dose</description>
        </group>
        <group group_id="P2">
          <title>Active Doxycycline + Placebo Azithromycin</title>
          <description>Doxycycline : one 100mg capsule administered twice daily for seven days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="304"/>
                <participants group_id="P2" count="302"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="245"/>
                <participants group_id="P2" count="238"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="64"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active Azithromycin + Placebo Doxycycline</title>
          <description>Azithromycin : two 500mg tablets or four 250mg tablets administered as a single dose</description>
        </group>
        <group group_id="B2">
          <title>Active Doxycycline + Placebo Azithromycin</title>
          <description>Doxycycline : one 100mg capsule administered twice daily for seven days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="304"/>
            <count group_id="B2" value="302"/>
            <count group_id="B3" value="606"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.1" spread="9.8"/>
                    <measurement group_id="B2" value="33.3" spread="10.1"/>
                    <measurement group_id="B3" value="33.7" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="304"/>
                    <measurement group_id="B2" value="302"/>
                    <measurement group_id="B3" value="606"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="304"/>
                    <measurement group_id="B2" value="302"/>
                    <measurement group_id="B3" value="606"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>mITT Analysis of Eradication of M. Genitalium at First Follow-up Study Visit</title>
        <description>Microbiologic cure of M. genitalium at first follow-up visit (defined as a negative in-house PCR test performed on urine)</description>
        <time_frame>approximately 3 weeks after initial study visit (allowable window is 2-5 weeks after initial study visit)</time_frame>
        <population>mITT population (defined as urethral symptoms or visible discharge plus &gt;=5PMNs/HPF at baseline) who tested positive for M. genitalium at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Active Azithromycin + Placebo Doxycycline</title>
            <description>Azithromycin : two 500mg tablets or four 250mg tablets administered as a single dose</description>
          </group>
          <group group_id="O2">
            <title>Active Doxycycline + Placebo Azithromycin</title>
            <description>Doxycycline : one 100mg capsule administered twice daily for seven days</description>
          </group>
        </group_list>
        <measure>
          <title>mITT Analysis of Eradication of M. Genitalium at First Follow-up Study Visit</title>
          <description>Microbiologic cure of M. genitalium at first follow-up visit (defined as a negative in-house PCR test performed on urine)</description>
          <population>mITT population (defined as urethral symptoms or visible discharge plus &gt;=5PMNs/HPF at baseline) who tested positive for M. genitalium at baseline</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minimum Inhibitory Concentrations (MIC) of All Cultivable Strains of M. Genitalium and Ureaplasmas</title>
        <time_frame>on-going</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cure as Measured by the Absence of Recurrent or Persistent Signs and/or Symptoms of Urethral Infection Among Case Subjects Who Were Positive for M. Genitalium or Ureaplasmas at the Initial Study Visit</title>
        <time_frame>approximately 3 weeks after initial study visit (allowable window is 2-5 weeks after initial study visit)</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>mITT Analysis of Eradication of U. Urealyticum at First Follow-up Visit</title>
        <description>Microbiologic cure, defined as negative PCR for U. urealyticum (if cultured), or negative culture at first follow-up visit</description>
        <time_frame>3 weeks (allowable window 2-5)</time_frame>
        <population>mITT population (defined as urethral symptoms or visible discharge plus &gt;=5PMNs/HPF at baseline) who tested positive for U. urealyticum at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Active Azithromycin + Placebo Doxycycline</title>
            <description>Azithromycin : two 500mg tablets or four 250mg tablets administered as a single dose</description>
          </group>
          <group group_id="O2">
            <title>Active Doxycycline + Placebo Azithromycin</title>
            <description>Doxycycline : one 100mg capsule administered twice daily for seven days</description>
          </group>
        </group_list>
        <measure>
          <title>mITT Analysis of Eradication of U. Urealyticum at First Follow-up Visit</title>
          <description>Microbiologic cure, defined as negative PCR for U. urealyticum (if cultured), or negative culture at first follow-up visit</description>
          <population>mITT population (defined as urethral symptoms or visible discharge plus &gt;=5PMNs/HPF at baseline) who tested positive for U. urealyticum at baseline</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Active Azithromycin + Placebo Doxycycline</title>
          <description>Azithromycin : two 500mg tablets or four 250mg tablets administered as a single dose</description>
        </group>
        <group group_id="E2">
          <title>Active Doxycycline + Placebo Azithromycin</title>
          <description>Doxycycline : one 100mg capsule administered twice daily for seven days</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Broken leg</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="304"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Unstable mental status</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="304"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="304"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="73" subjects_affected="28" subjects_at_risk="304"/>
                <counts group_id="E2" events="68" subjects_affected="36" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="74" subjects_affected="31" subjects_at_risk="304"/>
                <counts group_id="E2" events="47" subjects_affected="35" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <description>flu, cold, URTI; STD/genital injury or pain; dizziness; injuries; dry mouth; non-rash skin condition);elective medical procedure; mild bleeding; sunburn; tightness in head, neck</description>
                <counts group_id="E1" events="32" subjects_affected="12" subjects_at_risk="304"/>
                <counts group_id="E2" events="32" subjects_affected="17" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="304"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="302"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="304"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="302"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lisa E. Manhart, PhD - PI</name_or_title>
      <organization>University of Washington</organization>
      <phone>206-744-3646</phone>
      <email>lmanhart@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

